Evidence map›Paper›PMID 32699108›Full record

ArticleBMJ open diabetes research & care2020

Clinical characterization of data-driven diabetes subgroups in Mexicans using a reproducible machine learning approach.

Omar Yaxmehen Bello-Chavolla, Jessica Paola Bahena-López, Arsenio Vargas-Vázquez, Neftali Eduardo Antonio-Villa, Alejandro Márquez-Salinas, Carlos A Fermín-Martínez, Rosalba Rojas, Roopa Mehta, Ivette Cruz-Bautista, Sergio Hernández-Jiménez and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06120556 (Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes), which is not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06120556 completedstarted 2023, after this paper: background citation

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes: an Italian Monocentric Retrospective Study

Ran2023Enrolled130Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsGLP-1 receptor agonist
PMID 31047901PMID 29503172other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Type 2 Diabetes Subtypes and Their Role in Metabolic Liver Disease and Fibrosis Progression.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Omar Yaxmehen Bello-ChavollaUnidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Tlalpan, Mexico.ORCID 0000-0003-3093-937X
Jessica Paola Bahena-LópezMD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México, Coyoacan, Mexico.
Arsenio Vargas-VázquezUnidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Tlalpan, Mexico.
Neftali Eduardo Antonio-VillaUnidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Tlalpan, Mexico.
Alejandro Márquez-SalinasMD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México, Coyoacan, Mexico.
Carlos A Fermín-MartínezMD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México, Coyoacan, Mexico.ORCID 0000-0001-5627-8851
Rosalba RojasInstituto Nacional de Salud Publica, Cuernavaca, Mexico.
Roopa MehtaUnidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Tlalpan, Mexico.
Ivette Cruz-BautistaUnidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Tlalpan, Mexico.
Sergio Hernández-JiménezCenter of Comprehensive Care for the Patient with Diabetes, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Ana Cristina García-UlloaCenter of Comprehensive Care for the Patient with Diabetes, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Paloma Almeda-ValdesDepartment of Endocrinology and Metabolism, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Tlalpan, Mexico.
Carlos Alberto Aguilar-SalinasUnidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Tlalpan, Mexico caguilarsalinas@yahoo.com.ORCID 0000-0001-8517-0241
Metabolic Syndrome Study Group
Group of Study CAIPaDi
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXUniversidad Nacional Autónoma de México · MXInstituto Nacional de Salud Pública · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrevious reports in European populations demonstrated the existence of five data-driven adult-onset diabetes subgroups. Here, we use self-normalizing neural networks (SNNN) to improve reproducibility of these data-driven diabetes subgroups in Mexican cohorts to extend its application to more diverse settings. RESEARCH DESIGN AND

methodsWe trained SNNN and compared it with k-means clustering to classify diabetes subgroups in a multiethnic and representative population-based National Health and Nutrition Examination Survey (NHANES) datasets with all available measures (training sample: NHANES-III, n=1132; validation sample: NHANES 1999-2006, n=626). SNNN models were then applied to four Mexican cohorts (SIGMA-UIEM, n=1521; Metabolic Syndrome cohort, n=6144; ENSANUT 2016, n=614 and CAIPaDi, n=1608) to characterize diabetes subgroups in Mexicans according to treatment response, risk for chronic complications and risk factors for the incidence of each subgroup.

resultsSNNN yielded four reproducible clinical profiles (obesity related, insulin deficient, insulin resistant, age related) in NHANES and Mexican cohorts even without C-peptide measurements. We observed in a population-based survey a high prevalence of the insulin-deficient form (41.25%, 95% CI 41.02% to 41.48%), followed by obesity-related (33.60%, 95% CI 33.40% to 33.79%), age-related (14.72%, 95% CI 14.63% to 14.82%) and severe insulin-resistant groups. A significant association was found between the SLC16A11 diabetes risk variant and the obesity-related subgroup (OR 1.42, 95% CI 1.10 to 1.83, p=0.008). Among incident cases, we observed a greater incidence of mild obesity-related diabetes (n=149, 45.0%). In a diabetes outpatient clinic cohort, we observed increased 1-year risk (HR 1.59, 95% CI 1.01 to 2.51) and 2-year risk (HR 1.94, 95% CI 1.13 to 3.31) for incident retinopathy in the insulin-deficient group and decreased 2-year diabetic retinopathy risk for the obesity-related subgroup (HR 0.49, 95% CI 0.27 to 0.89).

conclusionsDiabetes subgroup phenotypes are reproducible using SNNN; our algorithm is available as web-based tool. Application of these models allowed for better characterization of diabetes subgroups and risk factors in Mexicans that could have clinical applications.

Indexed as

Diabetes Mellitus, Type 2Metabolic SyndromeHumansMachine LearningNutrition SurveysReproducibility of Resultsethnic groupsinsulin resistancestatistical modelstype 2 diabetes mellitus

Identifiers

PMID32699108
PMCPMC7380860
OpenAlexW3044475857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.